InVivoSIM anti-human PD-L1 (Atezolizumab Biosimilar)
Catalog #SIM0009
Clone:
Atezolizumab
Reactivities:
Human
Product Details
This non-therapeutic biosimilar antibody uses the same variable regions from the therapeutic antibody Atezolizumab making it ideal for research use. This Atezolizumab biosimilar reacts with human PD-L1 (programmed death ligand 1) also known as B7-H1 or CD274. PD-L1 is a 40 kDa type I transmembrane protein that belongs to the B7 family of the Ig superfamily. PD-L1 is expressed on T lymphocytes, B lymphocytes, NK cells, dendritic cells, as well as IFNĪ³ stimulated monocytes, epithelial cells and endothelial cells. PD-L1 binds to its receptor, PD-1, found on CD4 and CD8 thymocytes as well as activated T and B lymphocytes and myeloid cells. Engagement of PD-L1 with PD-1 leads to inhibition of TCR-mediated T cell proliferation and cytokine production. PD-L1 is thought to play an important role in tumor immune evasion. Induced PD-L1 expression is common in many tumors and results in increased resistance of tumor cells to CD8 T cell mediated lysis. Atezolizumab blocks the interaction of PD-L1 with PD-1 and CD80.Specifications
Isotype | Human IgG1 |
---|---|
Recommended Isotype Control(s) | RecombiMAb human IgG1 (N297A) isotype control, anti-hen egg lysozyme |
Recommended Dilution Buffer | InVivoPure pH 7.0 Dilution Buffer |
Immunogen | Not available or unknown |
Reported Applications |
Flow Cytometry Western Blot |
Formulation |
PBS, pH 7.0 Contains no stabilizers or preservatives |
Endotoxin |
<1EU/mg (<0.001EU/Ī¼g) Determined by LAL gel clotting assay |
Sterility | 0.2 Āµm filtration |
Production | Purified from cell culture supernatant |
Purification | Protein A |
RRID | AB_2894730 |
Molecular Weight | 150 kDa |
Storage | The antibody solution should be stored at the stock concentration at 4Ā°C. Do not freeze. |